4basebio (4BB) Stock Overview
Engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4BB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
4basebio PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£9.85 |
| 52 Week High | UK£15.50 |
| 52 Week Low | UK£9.40 |
| Beta | 1 |
| 1 Month Change | 0% |
| 3 Month Change | -12.44% |
| 1 Year Change | -34.33% |
| 3 Year Change | 109.57% |
| 5 Year Change | n/a |
| Change since IPO | 191.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4BB | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -1.5% | 5.7% | 0.7% |
| 1Y | -34.3% | -1.7% | 5.7% |
Return vs Industry: 4BB underperformed the UK Biotechs industry which returned -1.7% over the past year.
Return vs Market: 4BB underperformed the UK Market which returned 5.7% over the past year.
Price Volatility
| 4BB volatility | |
|---|---|
| 4BB Average Weekly Movement | 2.6% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 4BB has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 4BB's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 110 | Heikki Lanckriet | www.4basebio.com |
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5’ and 3’ ends for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA product for in vitro transcription processes for the production of mRNA for use in vaccines and therapeutics; and oeDNA, or open ended DNA, a linear, double stranded DNA product ideal for genome editing. It also provides osDNA, or open stabilized DNA, a product incorporating nucleotide modifications within the DNA backbone enables tuning of the immunostimulatory properties of the construct for DNA vaccine applications; and The Hermes, a proprietary delivery platform for nucleic acid and protein payloads appears to offer a thermo-stable alternative to traditional lipid based delivery systems.
4basebio PLC Fundamentals Summary
| 4BB fundamental statistics | |
|---|---|
| Market cap | UK£153.23m |
| Earnings (TTM) | -UK£12.33m |
| Revenue (TTM) | UK£933.00k |
Is 4BB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4BB income statement (TTM) | |
|---|---|
| Revenue | UK£933.00k |
| Cost of Revenue | UK£303.00k |
| Gross Profit | UK£630.00k |
| Other Expenses | UK£12.96m |
| Earnings | -UK£12.33m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.80 |
| Gross Margin | 67.52% |
| Net Profit Margin | -1,321.87% |
| Debt/Equity Ratio | 54.7% |
How did 4BB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/17 21:24 |
| End of Day Share Price | 2025/07/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
4basebio PLC is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pierre Sylvain Rousseau | Barclays |
| Adam McCarter | Cavendish |
| Charles Weston | RBC Capital Markets |